PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 112 filers reported holding PHATHOM PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.31 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $811,391 | -21.7% | 78,244 | +8.1% | 0.00% | – |
| Q2 2023 | $1,036,511 | +54.9% | 72,382 | -22.7% | 0.00% | – |
| Q1 2023 | $669,003 | -13.8% | 93,698 | +35.4% | 0.00% | – |
| Q4 2022 | $776,290 | -24.3% | 69,188 | -25.1% | 0.00% | – |
| Q3 2022 | $1,025,000 | +11.5% | 92,430 | -15.1% | 0.00% | – |
| Q2 2022 | $919,000 | -20.2% | 108,862 | +28.7% | 0.00% | – |
| Q1 2022 | $1,151,000 | -58.0% | 84,600 | -39.2% | 0.00% | – |
| Q4 2021 | $2,738,000 | +219.5% | 139,168 | +420.6% | 0.00% | – |
| Q3 2021 | $857,000 | -4.4% | 26,733 | +0.9% | 0.00% | – |
| Q2 2021 | $896,000 | +44700.0% | 26,492 | +44801.7% | 0.00% | – |
| Q1 2021 | $2,000 | -99.2% | 59 | -99.3% | 0.00% | – |
| Q4 2020 | $264,000 | +560.0% | 7,933 | +624.5% | 0.00% | – |
| Q3 2020 | $40,000 | -63.6% | 1,095 | -67.1% | 0.00% | – |
| Q2 2020 | $110,000 | +423.8% | 3,332 | +300.5% | 0.00% | – |
| Q1 2020 | $21,000 | -95.3% | 832 | -94.2% | 0.00% | – |
| Q4 2019 | $450,000 | – | 14,441 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 2,484,274 | $27,873,554 | 11.71% |
| Frazier Life Sciences Management, L.P. | 8,407,152 | $94,328,245 | 5.86% |
| Abingworth LLP | 1,435,106 | $16,101,889 | 5.25% |
| Opaleye Management Inc. | 417,500 | $4,684,350 | 1.63% |
| 683 Capital Management, LLC | 1,350,000 | $15,147,000 | 1.28% |
| Newtyn Management, LLC | 484,074 | $5,431,310 | 1.12% |
| Penn Mutual Asset Management | 62,802 | $704,638 | 0.79% |
| StepStone Group LP | 422,085 | $4,735,794 | 0.62% |
| MPM BioImpact LLC | 195,942 | $2,198,469 | 0.57% |
| Avidity Partners Management LP | 1,900,000 | $21,318,000 | 0.46% |